{"analyses":[{"ciLowerLimit":"0.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.32","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"< 0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.18","statisticalComment":"P-value is from stratified log-rank test, adjusted for randomization stratification factors.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"10.7","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"7.1","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG001","title":"Placebo + Rituximab"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Analysis Set: randomized participants with treatment group designated according to initial randomization.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"months"}